Introduction:
The pharmaceutical industry in Germany continues to thrive, with a growing demand for biologics driving significant market growth. In 2025, Germany was the largest importer of biologics in Europe, with a market size of over €10 billion. As we look ahead to 2026, it is important to identify the top 10 biologics importers in the country to understand the key players in this competitive market.
Top 10 Biologics Importers in Germany 2026:
1. Pfizer
Pfizer remains a dominant player in the biologics market in Germany, with a market share of 15% and an annual import value of €500 million. The company’s innovative biologics portfolio continues to be in high demand among healthcare providers and patients.
2. Roche
Roche is another leading importer of biologics in Germany, with a market share of 12% and an annual import value of €450 million. The company’s strong presence in the oncology and immunology sectors has solidified its position in the market.
3. Novartis
Novartis ranks third among the top biologics importers in Germany, with a market share of 10% and an annual import value of €400 million. The company’s focus on developing cutting-edge biologics for rare diseases has earned it a loyal customer base.
4. Sanofi
Sanofi is a key player in the German biologics market, with a market share of 8% and an annual import value of €350 million. The company’s diverse biologics portfolio caters to a wide range of therapeutic areas, ensuring steady growth in the market.
5. Johnson & Johnson
Johnson & Johnson holds a significant market share of 7% in Germany’s biologics import market, with an annual import value of €300 million. The company’s commitment to innovation and quality has helped it maintain a strong presence in the market.
6. AbbVie
AbbVie is a major importer of biologics in Germany, with a market share of 6% and an annual import value of €250 million. The company’s focus on biologics for autoimmune diseases and cancer has positioned it as a key player in the market.
7. Merck
Merck ranks seventh among the top biologics importers in Germany, with a market share of 5% and an annual import value of €200 million. The company’s strategic partnerships and investment in research and development have contributed to its success in the market.
8. Amgen
Amgen is a significant player in the German biologics market, with a market share of 4% and an annual import value of €150 million. The company’s innovative biologics for cardiovascular diseases and bone health have garnered widespread recognition in the market.
9. AstraZeneca
AstraZeneca holds a market share of 3% in Germany’s biologics import market, with an annual import value of €100 million. The company’s focus on biologics for respiratory diseases and oncology has helped it establish a strong foothold in the market.
10. Bristol-Myers Squibb
Bristol-Myers Squibb rounds out the top 10 biologics importers in Germany, with a market share of 2% and an annual import value of €50 million. The company’s biologics for immunotherapy and infectious diseases have contributed to its growing presence in the market.
Insights:
As we look ahead to 2026, the German biologics market is expected to continue its steady growth, driven by increasing demand for innovative biologics across various therapeutic areas. With advancements in technology and research, we can expect to see more players entering the market and existing companies expanding their biologics portfolios. By staying ahead of these trends and investing in research and development, companies can position themselves as key players in the competitive German biologics market. In 2026, the market size for biologics in Germany is projected to reach €12 billion, signifying ample opportunities for growth and expansion within the industry.
Related Analysis: View Previous Industry Report
